Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The biodisposition and hypertrichotic effects of bimatoprost in mouse skin.

Woodward DF, Tang ES, Attar M, Wang JW.

Exp Dermatol. 2013 Feb;22(2):145-8. doi: 10.1111/exd.12071. Epub 2013 Jan 2.

2.

Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.

Giannico AT, Lima L, Russ HH, Montiani-Ferreira F.

J Ocul Pharmacol Ther. 2013 Nov;29(9):817-20. doi: 10.1089/jop.2013.0075. Epub 2013 Aug 27.

PMID:
23981234
3.

Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost.

Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E.

Br J Dermatol. 2010 Jun;162(6):1186-97. doi: 10.1111/j.1365-2133.2010.09685.x. Epub 2010 Mar 12.

PMID:
20346040
4.

Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost.

Hart J, Shafranov G.

Am J Ophthalmol. 2004 Apr;137(4):756-7.

PMID:
15059720
5.

Hypertrichosis of the eyelashes caused by bimatoprost.

Tosti A, Pazzaglia M, Voudouris S, Tosti G.

J Am Acad Dermatol. 2004 Nov;51(5 Suppl):S149-50. Erratum in: J Am Acad Dermatol. 2004 Dec;51(6):1040.

PMID:
15577756
6.

Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.

Woodward DF, Wang JW, Poloso NJ.

Pharmacol Rev. 2013 Jul 26;65(4):1135-47. doi: 10.1124/pr.112.007088. Print 2013. Review.

7.

Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.

Smith S, Fagien S, Whitcup SM, Ledon F, Somogyi C, Weng E, Beddingfield FC 3rd.

J Am Acad Dermatol. 2012 May;66(5):801-6. doi: 10.1016/j.jaad.2011.06.005. Epub 2011 Sep 6.

PMID:
21899919
8.

Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost.

Herane MI, Urbina F.

J Eur Acad Dermatol Venereol. 2004 Sep;18(5):644-5. No abstract available.

PMID:
15324422
9.

Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes.

Wester ST, Lee WW, Shi W.

Ophthalmology. 2010 May;117(5):1024-31. doi: 10.1016/j.ophtha.2009.10.017. Epub 2010 Feb 16.

10.

Iris heterochromia and unilateral eyelash hypertrichosis.

Rao RC, Ballard TN, Chen TC.

JAMA. 2015 May 19;313(19):1967-8. doi: 10.1001/jama.2015.1348. No abstract available.

11.

Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.

Easthope SE, Perry CM.

Drugs Aging. 2002;19(3):231-48. Review.

PMID:
12027782
12.

The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias.

Khidhir KG, Woodward DF, Farjo NP, Farjo BK, Tang ES, Wang JW, Picksley SM, Randall VA.

FASEB J. 2013 Feb;27(2):557-67. doi: 10.1096/fj.12-218156. Epub 2012 Oct 26.

13.

Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.

Centofanti M, Oddone F, Chimenti S, Tanga L, Citarella L, Manni G.

Am J Ophthalmol. 2006 Dec;142(6):1059-60. Epub 2006 Aug 7.

PMID:
17157592
14.

Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth.

Cohen JL.

Dermatol Surg. 2010 Sep;36(9):1361-71. doi: 10.1111/j.1524-4725.2010.01522.x. Review.

PMID:
20384750
15.

[Hyperpigmentosis and hypertrichosis of the eyelids after use of bimatoprost eye drops].

Modschiedler K, von den Driesch P, Paus R.

J Dtsch Dermatol Ges. 2005 Apr;3(4):276-7. German.

PMID:
16370476
16.

Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth.

Yoelin S, Walt JG, Earl M.

Dermatol Surg. 2010 May;36(5):638-49. doi: 10.1111/j.1524-4725.2010.01519.x. Epub 2010 Apr 1.

PMID:
20384751
17.

Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice.

Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN.

Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4571-7.

PMID:
16303950
18.

Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.

Ahluwalia GS.

J Investig Dermatol Symp Proc. 2013 Dec;16(1):S73-6. doi: 10.1038/jidsymp.2013.30.

19.

Cellular basis for bimatoprost effects on human conventional outflow.

Stamer WD, Piwnica D, Jolas T, Carling RW, Cornell CL, Fliri H, Martos J, Pettit SN, Wang JW, Woodward DF.

Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5176-81. doi: 10.1167/iovs.09-4955. Epub 2010 Apr 30.

20.

Clinical management of trichotillomania with bimatoprost.

Peabody T, Reitz S, Smith J, Teti B.

Optom Vis Sci. 2013 Jun;90(6):e167-71. doi: 10.1097/OPX.0b013e318294c158.

PMID:
23645373

Supplemental Content

Support Center